Castle Biosciences (CSTL) Preferred Stock Liabilities (2018 - 2019)

Castle Biosciences has disclosed Preferred Stock Liabilities across 2 years of filings, most recently posting $45.1 million for Q2 2019.

• Preferred Stock Liabilities for Q2 2019 came in at $45.1 million, up 2905.19% year-over-year; the trailing twelve-month figure through Jun 2019 was $45.1 million (up 2905.19% YoY), and the FY2018 annual result was $45.0 million, changed N/A from the prior year.
• Preferred Stock Liabilities came in at $45.1 million for Q2 2019 at Castle Biosciences, roughly flat from $45.1 million in the prior quarter.
• In the past five years, Preferred Stock Liabilities ranged from a high of $45.1 million in Q2 2019 to a low of $1.5 million in Q1 2018.